Cartesian Therapeutics, Inc. Common Stock (RNAC) is a publicly traded Healthcare sector company. As of May 21, 2026, RNAC trades at $6.50 with a market cap of $202.44M and a P/E ratio of -1.27. RNAC moved +7.31% today. Year to date, RNAC is -5.64%; over the trailing twelve months it is -36.27%. Its 52-week range spans $5.60 to $26.50. Analyst consensus is strong buy with an average price target of $32.20. Rallies surfaces RNAC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Cartesian Reports $120.4M Cash, Advances Three Descartes-08 Trials: Cartesian Therapeutics held $120.4M cash as of March 31, 2026, funding operations into mid-2027 while enrolling ~100 patients in its Phase 3 AURORA myasthenia gravis trial and initiating Phase 2 TRITON in dermatomyositis and antisynthetase syndrome with pediatric HELIOS enrollments. R&D expenses rose to $19.5M, net loss widened to $39.2M.
| Metric | Value |
|---|---|
| Price | $6.50 |
| Market Cap | $202.44M |
| P/E Ratio | -1.27 |
| EPS | $-5.02 |
| Dividend Yield | 0.00% |
| 52-Week High | $26.50 |
| 52-Week Low | $5.60 |
| Volume | 900 |
| Avg Volume | 0 |
| Revenue (TTM) | $2.80M |
| Net Income | $-130.30M |
| Gross Margin | 0.00% |
6 analysts cover RNAC: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.20.